上海凯宝(300039) - 2025 Q2 - 季度财报

Section I Important Notice, Table of Contents, and Definitions Important Notice The company's board, supervisory board, and senior management guarantee the report's accuracy, while the financial officers confirm the financial statements' integrity - The company's board, supervisory board, and senior management guarantee the semi-annual report's content is true, accurate, and complete, with no false records, misleading statements, or major omissions[3] - Company head Mu Jingwei, chief financial officer Chen Youlong, and head of accounting Li Yaru declare that the financial report is true, accurate, and complete[3] - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[4] Table of Contents This section lists the eight main chapters of the semi-annual report, covering important notices, company profile, management discussion, corporate governance, significant events, share changes, bond information, and financial reports - The report contains eight main chapters, from important notices to financial reports[6] Reference Documents This section lists documents available for inspection, including the original semi-annual report, signed financial statements, and publicly disclosed company announcements - Reference documents include the original 2025 semi-annual report signed by the chairman, signed and sealed financial report texts, and original copies of all company documents and announcements publicly disclosed during the reporting period[8] - Reference documents are available at the company's Board of Directors Office[9] Definitions This section defines common terms and abbreviations used in the report, covering regulatory bodies, exchanges, company entities, and the reporting period - Defines regulatory bodies such as the China Securities Regulatory Commission, Shenzhen Stock Exchange, and National Medical Products Administration[10] - Clarifies that "the Company" and "Shanghai Kaibao" refer to Shanghai Kaibao Pharmaceutical Co., Ltd[10] - The reporting period refers to January 1, 2025, to June 30, 2025[10] Section II Company Profile and Key Financial Indicators 1. Company Profile The company, listed on the Shenzhen Stock Exchange under stock code 300039, is officially known as Shanghai Kaibao Pharmaceutical Co., Ltd - Stock Abbreviation: Shanghai Kaibao, Stock Code: 300039[12] - Stock Exchange: Shenzhen Stock Exchange[12] - Legal Representative of the Company: Mu Jingwei[12] 2. Contact Persons and Information This section provides contact details for the company's Board Secretary and Securities Affairs Representative for investor communication - Board Secretary: Ren Liwang, Contact Number: 021-37572069, Email: kbyydmb@126.com[13] - Securities Affairs Representative: Ma Congying, Contact Number: 021-37572069, Email: kbyydmb@126.com[13] 3. Other Information No changes occurred in the company's contact information, disclosure channels, or registration details during the reporting period - The company's registered address, office address and postal code, website, and email address remained unchanged during the reporting period[14] - The securities exchange website and media names and URLs for the company's semi-annual report disclosure, and the location for semi-annual report availability, remained unchanged during the reporting period[15] - The company's registration status remained unchanged during the reporting period[16] 4. Key Accounting Data and Financial Indicators The company's operating revenue and net profit attributable to shareholders decreased, while operating cash flow, total assets, and net assets increased Major Accounting Data and Financial Indicators (Current Period vs. Prior Period) | Indicator | Current Period (yuan) | Prior Period (yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 604,655,893.63 | 829,151,714.24 | -27.08% | | Net Profit Attributable to Parent Company Shareholders | 121,954,089.17 | 142,139,016.05 | -14.20% | | Net Profit Attributable to Parent Company Shareholders After Non-Recurring Gains and Losses | 117,382,833.75 | 142,818,008.61 | -17.81% | | Net Cash Flow from Operating Activities | 159,806,070.06 | 131,071,740.10 | 21.92% | | Basic EPS (yuan/share) | 0.1166 | 0.1359 | -14.20% | | Diluted EPS (yuan/share) | 0.1166 | 0.1359 | -14.20% | | Weighted Average ROE (%) | 6.31% | -10.92% | 17.23% | Major Accounting Data and Financial Indicators (Period-End vs. Prior Year-End) | Indicator | Period-End (yuan) | Prior Year-End (yuan) | Period-End vs. Prior Year-End Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 4,674,066,400.80 | 4,518,469,414.47 | 3.44% | | Net Assets Attributable to Parent Company Shareholders | 4,263,452,029.25 | 4,102,051,563.35 | 3.93% | 5. Differences in Accounting Data Under Domestic and Overseas Accounting Standards The company reported no differences in net profit and net assets between Chinese and international or overseas accounting standards - The company reported no differences in net profit and net assets between financial reports disclosed under International Accounting Standards and Chinese Accounting Standards during the reporting period[18] - The company reported no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and Chinese Accounting Standards during the reporting period[19] 6. Non-Recurring Gains and Losses and Amounts Non-recurring gains and losses totaled 4.57 million yuan, primarily from asset disposal, government grants, and fair value changes of financial assets Non-Recurring Gains and Losses and Amounts | Item | Amount (yuan) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets (incl. write-back of impairment provisions) | 187,254.57 | | Government Grants Recognized in Current P&L (excluding those closely related to normal operations, policy-compliant, standard-based, and with continuous impact) | 2,569,578.24 | | Gains/Losses from Fair Value Changes and Disposal of Financial Assets/Liabilities Held by Non-Financial Enterprises (excluding effective hedging related to normal operations) | 2,941,585.75 | | Other Non-Operating Income and Expenses | -403,599.18 | | Less: Income Tax Impact | 723,524.75 | | Minority Interest Impact (after tax) | 39.21 | | Total | 4,571,255.42 | - The company has no other profit and loss items that meet the definition of non-recurring gains and losses, nor does it classify non-recurring gains and losses as recurring gains and losses[22] Section III Management Discussion and Analysis 1. Principal Business Activities During the Reporting Period The company primarily engages in modern Chinese medicine R&D, production, and sales, with a focus on respiratory, cardiovascular, and digestive product lines (I) Overview of the Industry The pharmaceutical manufacturing industry, particularly traditional Chinese medicine, continues to grow with supportive policies focusing on innovation and quality - Pharmaceutical manufacturing is a vital component of the national economy, with continuously rising market demand, and traditional Chinese medicine holds unique advantages and value[24] - In the first half of 2025, pharmaceutical industry policies were intensively introduced around three main themes: "inheriting innovation, quality improvement, and industrial upgrading," promoting high-quality industry development[24] - Policies include the "Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation to Promote High-Quality Development of the Pharmaceutical Industry" and the "Opinions on Improving the Quality of Traditional Chinese Medicine to Promote High-Quality Development of the Traditional Chinese Medicine Industry"[24][25] (II) Company's Industry Position As a Shanghai High-Tech Enterprise, the company holds a strong market position with its patented Tanreqing Injection, a national strategic reserve medicine - The company is a Shanghai High-Tech Enterprise, committed to the modernization of traditional Chinese medicine, and was approved for **2